UCB (UCBJF) Stock Price, News & Analysis

Company Overview

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam). UCB also develops new therapies through internal research, collaborations and acquisitions.

Founded in 1928 by Emmanuel Janssen, UCB has grown from a chemical and pharmaceutical business into an international biopharmaceutical company. Headquartered in Brussels, Belgium, it serves patients and healthcare professionals across North America, Europe and other global markets through research, manufacturing and commercial operations.

Key Stats

• Today's Range: $305.31 to $316.84
• 50-Day Range: $231.75 to $317.34
• 52-Week Range: $219.60 to $345.39
• Volume: 3,864 shs
• Average Volume: 672 shs
• Market Capitalization: $59.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

UCB Stock Analysis - MarketRank™

UCB scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

UCB has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

UCB has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 49.58%

Earnings Growth

Earnings for UCB are expected to grow by 49.58% in the coming year, from $4.72 to $7.06 per share.

Price to Book Value per Share Ratio

UCB has a P/B Ratio of 6.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.54% of the float of UCB has been sold short.

Short Interest Ratio / Days to Cover

UCB has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in UCB has recently decreased by 14.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

UCB does not currently pay a dividend.

Dividend Growth

UCB does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for UCB this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, UCB insiders have not sold or bought any company stock.

Percentage Held by Institutions

UCB has minimal institutional ownership at this time.

Company Calendar

• Today: 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:UCBJF
• CIK: 1290640
• Web: www.ucb.com
• Phone: (322) 559-9999
• Fax: 32-2559-9900
• Employees: 10,117
• Year Founded: 1928

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 1.19
• Quick Ratio: 0.78

Sales & Book Value

• Annual Sales: $5.27 billion
• Price / Sales: 11.26
• Cash Flow: $13.48 per share
• Price / Cash Flow: 23.28
• Book Value: $50.52 per share
• Price / Book: 6.21

Miscellaneous

• Outstanding Shares: 189,020,000
• Free Float: N/A
• Market Cap: $59.32 billion
• Optionable: Not Optionable
• Beta: 0.47